Close Menu

NEW YORK — 4basebio on Friday reported a nearly 20 percent year-over-year increase in revenues for 2019 on strong performance by its genomics and recently divested proteomics and immunology businesses.

For the 12-month period ended Dec. 31, 4basebio's revenues climbed to €15.7 million ($17.0 million) from €13.1 million the year before. The firm attributed the higher revenues in part to the impact of a full year of revenues from TGR Biosciences, which was acquired in mid-2018.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.

Michael Caputo, the top Department of Health and Human Service spokesperson, is taking a leave of absence, CNN says.

CNBC reports that the CDC Director says a SARS-CoV-2 vaccine isn't likely to be generally available until the third quarter of 2021, timing President Donald Trump disputes.

In Nature this week: MassIVE.quant resource houses mass spectrometry-based proteomic data, influence of Viking genetics on European populations, and more.

Sponsored by
Beckman Coulter

This webinar will discuss a streamlined library preparation method for next-generation sequencing (NGS) that improves quality control testing capability while reducing the total number of steps compared to conventional multiplexed library workflows.